Patents by Inventor Junji Matsui
Junji Matsui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11933762Abstract: A metal structure evaluator for rolled steel sheets includes: a magnetic property measuring unit configured to measure a magnetic property of an evaluation target point in at least two or more different magnetization directions by performing, in the at least two or more different magnetization directions, processing of: applying a magnetic field on a surface of a rolled steel sheet in one direction; and measuring a magnetic property of the evaluation target point on the surface of the rolled steel sheet; and a determination unit configured to determine a metal structure of the evaluation target point based on the magnetic property measured by the magnetic property measuring unit.Type: GrantFiled: April 17, 2020Date of Patent: March 19, 2024Assignee: JFE STEEL CORPORATIONInventors: Takafumi Ozeki, Yutaka Matsui, Kenji Adachi, Junji Shimamura
-
Publication number: 20230212679Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.Type: ApplicationFiled: March 11, 2022Publication date: July 6, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
-
Patent number: 11608856Abstract: A linear motion guide unit includes a rail, a slider slidable relative to the rail, and rolling elements rollable in a rolling groove formed with the rail and the slider. The slider has a lubricating oil supply device provided at least at one end face thereof. The lubricating oil supply device includes a lubricating member that retains lubricating oil and abuts against a raceway surface of the rail to supply the lubricating oil to the rail, a housing having front, rear, and bottom surfaces covering front, rear, and bottom surfaces of the lubricating member, with an upper surface of the housing being left open, and a cover that covers at least an upper surface of the lubricating member. The housing is fixed to the slider with a first fixing member. The cover is fixed to the housing with a second fixing member, without being fixed with the first fixing member.Type: GrantFiled: December 14, 2021Date of Patent: March 21, 2023Assignee: NIPPON THOMPSON CO., LTD.Inventors: Masashi Matsui, Masatoshi Kondo, Yusuke Yamaguchi, Junji Matsui
-
Patent number: 11598776Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.Type: GrantFiled: March 23, 2018Date of Patent: March 7, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
-
Publication number: 20220186779Abstract: A linear motion guide unit includes a rail, a slider slidable relative to the rail, and rolling elements rollable in a rolling groove formed with the rail and the slider. The slider has a lubricating oil supply device provided at least at one end face thereof. The lubricating oil supply device includes a lubricating member that retains lubricating oil and abuts against a raceway surface of the rail to supply the lubricating oil to the rail, a housing having front, rear, and bottom surfaces covering front, rear, and bottom surfaces of the lubricating member, with an upper surface of the housing being left open, and a cover that covers at least an upper surface of the lubricating member. The housing is fixed to the slider with a first fixing member. The cover is fixed to the housing with a second fixing member, without being fixed with the first fixing member.Type: ApplicationFiled: December 14, 2021Publication date: June 16, 2022Inventors: Masashi MATSUI, Masatoshi KONDO, Yusuke YAMAGUCHI, Junji MATSUI
-
Patent number: 10945990Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.Type: GrantFiled: March 3, 2016Date of Patent: March 16, 2021Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
-
Publication number: 20200199689Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.Type: ApplicationFiled: March 4, 2020Publication date: June 25, 2020Applicant: Eisai R&D Management Co., Ltd.Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
-
Publication number: 20190111022Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 26, 2017Publication date: April 18, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Makoto Asano, Junji Matsui
-
Publication number: 20190000829Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.Type: ApplicationFiled: August 17, 2016Publication date: January 3, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Junji Matsui, Masahiro Matsuki, Akihiko Tsuruoka, Toshiyuki Tamai, Ryo Nakajima, Takuya Suzuki
-
Publication number: 20190000797Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.Type: ApplicationFiled: August 18, 2016Publication date: January 3, 2019Applicant: Eisai R&D Management Co., Ltd.Inventors: Kiyoshi Okamoto, Junji Matsui, Corina Dutcus
-
Publication number: 20180209980Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.Type: ApplicationFiled: March 23, 2018Publication date: July 26, 2018Applicant: Eisai R&D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
-
Patent number: 9969812Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: December 19, 2016Date of Patent: May 15, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9945862Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.Type: GrantFiled: May 31, 2012Date of Patent: April 17, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
-
Publication number: 20180071247Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.Type: ApplicationFiled: March 3, 2016Publication date: March 15, 2018Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.Inventors: Junji MATSUI, Gursel AKTAN, Vassiliki KARANTZA, RuiRong YUAN, Yasuhiro FUNAHASHI, Erhan BERRAK
-
Publication number: 20170191137Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.Type: ApplicationFiled: March 16, 2017Publication date: July 6, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
-
Publication number: 20170100367Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.Type: ApplicationFiled: May 27, 2015Publication date: April 13, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Makoto ASANO, Bruce A. LITTLEFIELD, Junji MATSUI, Martin OLIVO, Yoichi OZAWA, Yanke YU
-
Publication number: 20170096493Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: December 19, 2016Publication date: April 6, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9527921Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: April 14, 2016Date of Patent: December 27, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Publication number: 20160347858Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: April 14, 2016Publication date: December 1, 2016Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino
-
Patent number: 9006256Abstract: The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient.Type: GrantFiled: April 8, 2011Date of Patent: April 14, 2015Assignee: Eisai R&D Management Co., Ltd.Inventor: Junji Matsui